Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
14.91
+0.79 (5.59%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Crescent Biopharma Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Crescent Biopharma stock has a consensus rating of "Strong Buy" and an average price target of $31.5. The average 1-year stock price forecast is 111.27% higher than the current stock price, while the lowest is $27 (+81.09%) and the highest is $36 (+141.45%).
Price Target: $31.5 (+111.27%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Crescent Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 6 | 6 | 6 | 6 | 7 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $28 | Buy | Maintains | $28 | +87.79% | Oct 6, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Upgrades $36 | Buy | Upgrades | $36 | +141.45% | Oct 6, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $28 | Buy | Maintains | $28 | +87.79% | Oct 5, 2026 |
| Wedbush | Wedbush | Buy Maintains $27 | Buy | Maintains | $27 | +81.09% | Sep 14, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $35 | Buy | Maintains | $35 | +134.74% | Jun 23, 2026 |
Financial Forecast
Revenue This Year
1.73M
from 10.84M
Decreased by -84.09%
Revenue Next Year
4.79M
from 1.73M
Increased by 177.36%
EPS This Year
-2.35
from -12.81
EPS Next Year
-2.63
from -2.35
EPS and Forward PE are based on non-GAAP adjusted numbers.